How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,389 results for

Cerebrovascular Accident Risk in Women

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Management of Diabetes Mellitus in Primary Care

of clinical practice guidelines for the VA and DoD populations.[1] This clinical practice guideline (CPG) is intended to provide healthcare providers with a framework by which to evaluate, treat, and manage the individual needs and preferences of patients with diabetes mellitus (DM), thereby leading to improved clinical outcomes. The first VA/DoD CPG for the Management of Diabetes Mellitus, based upon earlier iterations in 1997 and 2000, was published in 2003.[2] It established a risk stratification (...) approach for setting individualized target goals based upon life expectancy, comorbid conditions, patient preferences, and absolute benefits and potential risks of therapy.[2] It also emphasized the risks of hypoglycemia. In 2010, the VA and DoD published a CPG for the Management of Diabetes Mellitus (2010 DM CPG), which was based on evidence reviewed through June 2009. Since the release of that guideline, a growing body of research has expanded the general knowledge and understanding of DM. Follow-up

2017 VA/DoD Clinical Practice Guidelines

182. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease

incidence of MI is 550,000 new and 200,000 recurrent attacks. The average age at first MI is 65.1 years for men and 72.0 years for women (1 [EL 4; NE]). Dyslipidemia is a primary, major risk factor for ASCVD and may even be a prerequisite for ASCVD, occurring before other major risk factors come into play. Epidemiologic data also suggest that hypercho- lesterolemia and perhaps coronary atherosclerosis itself are risk factors for ischemic cerebrovascular accident (CVA) (2 [EL 4; NE]). According to data (...) = cerebrovascu- lar; CVA = cerebrovascular accident; EL = evidence level; FH = familial hypercholesterolemia; FIELD = Secondary Endpoints from the Fenofibrate Intervention and Event Lowering in Diabetes trial; FOURIER = Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk trial; HATS = HDL-Atherosclerosis Treatment Study; HDL-C = high- density lipoprotein cholesterol; HeFH = heterozygous familial hypercholesterolemia; HHS = Helsinki Heart Study; HIV = human

2017 American Association of Clinical Endocrinologists

183. Arrhythmias in Congenital Heart Disease: A Position Paper of EHRA, AEPC, and ESC Working Group on Grown-up Congenital Heart Disease

angeborene Herzfehler ZAH, 3010 Bern, Switzerland; 34 Department of Woman and Child’s Health, University of Padua, Padua Italy; 35 Pediatric Arrhythmias, Electrophysiology and Sudden Death Unit, Department of Cardiology, Hospital Sant Joan de De ´u, Barcelona - Universitat de Barcelona, Passeig Sant Joan de De ´u, 2, 08950 Esplugues, Barcelona, Catalunya, Spain; 36 Gottsegen Gyorgy Orszagos Kardiologiai, Pediatric, Haller U. 29, Budapest HU-1096, Hungary; 37 Department of Pediatric Cardiology, University (...) of CHD predispose to arrhythmias even without any surgical intervention due to abnormalities of the conduction system, intrinsic structural pathology, and impact of pre- or post- operative cyanosis and volume-/pressure-overload. In general, surgery for congenital heart defects may result in sinus node dys- function, atrioventricular (AV) block and a variety of supraventric- ular and ventricular tachyarrhythmias including the risk of sudden cardiac death (SCD). Arrhythmia treatment in patients

2017 Heart Rhythm Society

184. Benign Paroxysmal Positional Vertigo (BPPV) Full Text available with Trip Pro

Practice Guideline: Benign Paroxysmal Positional Vertigo (Update) .entryAuthor" data-author-container-selector=".NLM_contrib-group"> Show all authors , MD 1 1Department of Otolaryngology, Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA by this author for this author , , MD 2 2Department of Otolaryngology, School of Medicine and Public Health, University of Colorado, Aurora, Colorado, USA by this author for this author , , MD, MPH 3 3Department of Otolaryngology (...) Information Volume: 156 issue: 3_suppl, page(s): S1-S47 Article first published online: March 1, 2017; Issue published: March 1, 2017 , MD 1 , , MD 2 , , MD, MPH 3 , , MD 4 , , MD 5 , , MD 6 , , PT, DPT, NCS 7 , 8 , , MSN, FNP-BC 9 , , PhD 10 , , MD 11 , , MD, PhD 12 , , MD 13 , , MD, PhD 14 , , MD 15 , 16 1 Department of Otolaryngology, Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA 2 Department of Otolaryngology, School of Medicine and Public Health, University

2017 American Academy of Otolaryngology - Head and Neck Surgery

185. Imaging Program Guidelines: Pediatric Imaging

nervous system pathology when suggested by the ophthalmologic exam Vascular indications This section contains indications for aneurysm, cerebrovascular accident/transient ischemic attack, hemorrhage/hematoma, and other vascular abnormalities. Aneurysm ? Screening in asymptomatic, high-risk individuals ? At least two (2) first degree relatives with intracranial aneurysm or subarachnoid hemorrhage ? Presence of a heritable condition which predisposes to intracranial aneurysm (examples include autosomal (...) years ? Follow-up after treatment with clips, endovascular coil or stenting Cerebrovascular accident (CVA or stroke) and transient ischemic attack (TIA) Hemorrhage/hematoma Other vascular abnormalities ? Arteriovenous malformation (AVM) ? Cavernous malformation ? Cerebral vein thrombosis ? Dural arteriovenous fistula (DAVF) ? Dural venous sinus thrombosis ? Venous angioma Note: CTA or MRA is generally preferred for these indications. CT Head – Pediatrics | Copyright © 2017. AIM Specialty Health. All

2017 AIM Specialty Health

186. Sleep Disorder Management Diagnostic & Treatment Guidelines

sleep study which did not diagnose OSA in a patient with ongoing clinical suspicion of OSA. 10. Patient is oxygen dependent for any reason 11. History of cerebrovascular accident (CVA) within the preceding 30 days 12. Chronic opiate narcotic use, when discontinuation is not an option. Diagnostic sleep testing for patients using opiate narcotics for acute self-limited conditions should ideally be deferred until the medications have been stopped. 13. Body Mass Index (BMI) >33 and elevated serum (...) (persistent hypertension in a patient taking three or more antihypertensive medications). Because of daytime sleepiness, deaths related to motor vehicle accidents are also more common in patients with OSA. Diagnosis of OSA: Although OSA may be suspected based on the symptoms described above, physical exam findings (e.g., obesity, increased neck circumference, retrognathia etc.), or presence of comorbidities, the diagnosis must be confirmed by a sleep test. During sleep testing, various physiological

2017 AIM Specialty Health

187. Integrating Tobacco Interventions into Daily Practice

? 3.0 Implementation Recommendation 3 .1: Provide clients with, or refer them to, intensive interventions and counselling on the use of pharmacotherapy, if they use tobacco and express an interest in reducing or quitting their tobacco use . Ia, V ? Recommendation 3 .2: Treat or refer all pregnant or postpartum women at every encounter for intensive behavioural counselling for tobacco harm reduction, cessation, and relapse prevention, in conjunction with nicotine replacement therapy, on a case (...) among a group of individuals. Hookah is also called shisha. Individuals who use hookah are exposed to the same health risks as individuals who smoke cigarettes (Centers for Disease Control and Prevention, 2016). Snuff Snuff is finely ground tobacco that may be either moist or dry and that often comes in different flavours. It is sold in cans or pouches. Moist snuff is spit free and is placed between the cheek and gum. Nicotine is absorbed through the buccal mucosa. Moist snuff products are also

2017 Registered Nurses' Association of Ontario

188. HTA of smoking cessation interventions

-term (six months or more) smoking cessation, and abstinence in late pregnancy in pregnant women. General adult population An updated systematic review identified 313 studies that met the inclusion criteria for the general adult population, half of which were published after January 2000. Sixty two percent of the studies had follow-up at 12 months or longer to estimate long-term abstinence. A quarter of the studies were considered at low risk of bias. Sixty five percent of the studies used (...) on the efficient and secure collection and sharing of health information, setting standards, evaluating information resources and publishing information about the delivery and performance of Ireland’s health and social care service. Health Technology Assessment (HTA) of smoking cessation interventions Health Information and Quality Authority 4 Foreword Given the higher risk of disease and death in smokers, the economic cost of smoking in Ireland is substantial. In 2013, the estimated cost to the healthcare

2017 Health Information and Quality Authority

189. Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia

no benefit in cognitive performance included: vitamin E in women; B 12 plus folic acid for executive/attention/processing speed; and angiotensin-converting enzyme plus thiazide versus placebo and angiotensin receptor blockers versus placebo on brief cognitive screening tests. We found low-strength evidence that the selective estrogen receptor modulator raloxifene reduced risk of probable MCI, but also that estrogen replacement with or without progesterone therapy increased risk of MCI and CATD. Physical (...) or prevent age-related cognitive decline, MCI, and/or CATD. A few specific interventions reached moderate strength evidence for no benefit in cognitive performance: vitamin E in women; and angiotensin converting enzyme and thiazide versus placebo and angiotensin receptor blockers versus placebo on specifically brief cognitive screening tests. We found low-strength evidence that the selective estrogen receptor modulator (SERM) raloxifene reduced risk of probable MCI. However, there was also low-strength

2017 Effective Health Care Program (AHRQ)

190. Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia

no benefit in cognitive performance included: vitamin E in women; B 12 plus folic acid for executive/attention/processing speed; and angiotensin-converting enzyme plus thiazide versus placebo and angiotensin receptor blockers versus placebo on brief cognitive screening tests. We found low-strength evidence that the selective estrogen receptor modulator raloxifene reduced risk of probable MCI, but also that estrogen replacement with or without progesterone therapy increased risk of MCI and CATD. Physical (...) or prevent age-related cognitive decline, MCI, and/or CATD. A few specific interventions reached moderate strength evidence for no benefit in cognitive performance: vitamin E in women; and angiotensin converting enzyme and thiazide versus placebo and angiotensin receptor blockers versus placebo on specifically brief cognitive screening tests. We found low-strength evidence that the selective estrogen receptor modulator (SERM) raloxifene reduced risk of probable MCI. However, there was also low-strength

2017 Effective Health Care Program (AHRQ)

191. Eculizumab for treating atypical haemolytic uraemic syndrome

studies (C10-003 and C10-004) is available; however, no deaths were reported in either study. In the retrospective C09-001r study, 73% (n=22) of patients reported at least 1 adverse reaction. Two (7%) deaths (due to a cerebrovascular accident and a Eculizumab for treating atypical haemolytic uraemic syndrome (HST1) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 11 of 45fatal carotid artery dissection), which were (...) of the body's defence against infection. The prognosis for people with aHUS is poor. Patients are at constant risk of sudden and progressive damage, and failure of vital organs. Mortality rates range from 10–15% in the acute phase of the disease and, within a year of diagnosis, up to 70% of patients progress to end-stage renal failure and need dialysis or die. One patient in 5 has aHUS affecting organs other than the kidneys, most commonly the brain or heart. 2.2 aHUS can occur at any age. Onset occurs

2015 National Institute for Health and Clinical Excellence - Highly specialised technology

192. Acute coronary syndrome

Acute coronary syndrome SIGN 148 • Acute coronary syndrome A national clinical guideline April 2016 EvidenceKEY TO EVIDENCE STATEMENTS AND RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 - Meta-analyses, systematic reviews, or RCTs with a high risk of bias 2 ++ High-quality systematic reviews of case-control or cohort (...) studies High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal 2 + Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal 2 - Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal 3 Non-analytic studies, eg case reports, case series 4 Expert opinion

2016 SIGN

193. Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)

, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Women at risk of pregnancy and seeking contraception Exclusion Criteria: Exclusion criteria based on approved prescribing information in India: Presence or history of venous thrombosis (...) , with or without pulmonary embolism. Presence or history of arterial thrombosis (e.g. cerebrovascular accident, myocardial infarction) or prodromi of a thrombosis (e.g. angina pectoris or transient ischemic attack). Known predisposition for venous or arterial thrombosis, with or without hereditary involvement such as Activated Protein C (APC) resistance, antithrombin-III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia and antiphospholipid antibodies (anticardiolipin antibodies

2011 Clinical Trials

194. Metformin for the Treatment of Premature Pubarche in Girls

decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 4 Years to 10 Years (Child) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Girls aged 4-10 with pubic hair prior to 8 years of age Elevated DHEAS level (...) or total bilirubin > 2.5 mg/dL. Renal disease defined as BUN > 30 mg/dL or serum creatinine > 1.4 mg/dL. Significant anemia (Hemoglobin < 10 mg/dL). History of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident. Known heart disease (New York Heart Association Class II or higher). Enrolled simultaneously into other investigative studies that require medications, proscribe the study medications, or otherwise prevent compliance with the protocol. Patients who anticipate taking longer

2011 Clinical Trials

195. A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants

Have a history or presence of cardiovascular disorder (including myocardial infarction, cerebrovascular accident, coronary artery disease, venous thromboembolism, arrhythmia [judged by the investigator to be clinically significant], or angina) within the last year, have symptoms or signs of congestive heart failure, or are expected to require coronary artery bypass surgery or angioplasty Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis (...) A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2011 Clinical Trials

196. Maternal cardiovascular events during childbirth among women with congenital heart disease. (Abstract)

, heart failure, cerebrovascular accident, embolism, death or a combined outcome) for women with and without CHD. Covariates included age, number of medical comorbidities, pulmonary hypertension, hospital teaching status, insurance status and method of delivery.Annual deliveries for women with CHD increased 34.9% from 1998 to 2007 compared with an increase of 21.3% in the general population. Women with CHD were more likely to sustain a cardiovascular event (4042/100,000 vs 278/100,000 deliveries (...) Maternal cardiovascular events during childbirth among women with congenital heart disease. To define the epidemiology of adverse cardiovascular events among women with congenital heart disease (CHD) hospitalised for childbirth in the USA.The 1998-2007 Nationwide Inpatient Sample, an administrative dataset representative of overall US hospital admissions, was used to identify hospitalisations for delivery.Logistic regression was used to estimate ORs for cardiovascular outcomes (arrhythmia

2011 Heart

197. Palbociclib (Ibrance) - locally advanced or metastatic breast cancer

represents about 12% of all new cancer cases and 25% of all cancers in women 2 . In Europe, there were an estimated 464,000 new cases of breast cancer (female) in 2012 and an estimated 131,000 deaths from the disease 3 . 2.1.3. Biologic features and clinical presentation The Rb pathway in breast cancer was recently described in a publication by Witkiewicz and Knudsen. In summary it is noted that in ER-positive breast cancer, Rb pathway deregulation is generally due to aberrant Cyclin D1 expression (...) . Biologic features and clinical presentation 10 2.1.4. Management 11 2.2. Quality aspects 13 2.2.1. Introduction 13 2.2.2. Active Substance 14 2.2.3. Finished Medicinal Product 17 2.2.4. Discussion on chemical, pharmaceutical and biological aspects 21 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects 21 2.3. Non-clinical aspects 21 2.3.1. Introduction 21 2.3.2. Pharmacology 22 2.3.3. Pharmacokinetics 24 2.3.4. Toxicology 25 2.3.5. Ecotoxicity/environmental risk assessment 28

2016 European Medicines Agency - EPARs

198. Uptravi (selexipag) - pulmonary arterial hypertension

Medicinal Product 11 2.2.4 Discussion on chemical, pharmaceutical and biological aspects 13 2.2.5 Conclusions on the chemical, pharmaceutical and biological aspects 13 2.2.6 Recommendation(s) for future quality development 13 2.3 Non-clinical aspects 14 2.3.1 Introduction 14 2.3.2 Pharmacology 14 2.3.3 Pharmacokinetics 18 2.3.4 Toxicology 21 2.3.5 Ecotoxicity/environmental risk assessment 29 2.3.6 Discussion on non-clinical aspects 29 2.3.7 Conclusion on non-clinical aspects 31 2.4 Clinical aspects 31 (...) 2.4.1 Introduction 31 2.4.2 Pharmacokinetics 32 2.4.3 Pharmacodynamics 38 2.4.4 Discussion on clinical pharmacology 40 2.4.5 Conclusions on clinical pharmacology 43 2.5 Clinical efficacy 44 2.5.1 Dose response studies 44 2.5.2 Main study 46 2.5.3 Discussion on clinical efficacy 70 2.5.4 Conclusions on clinical efficacy 74 2.6 Clinical safety 75 2.6.1 Discussion on clinical safety 88 2.6.2 Conclusions on clinical safety 90 2.7 Risk Management Plan 90 2.8 Pharmacovigilance 102 2.9 Product information

2016 European Medicines Agency - EPARs

199. Tagrisso - osimertinib

, and pharmaceutical aspects 18 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects 18 2.2.6. Recommendations for future quality development 18 2.3. Non-clinical aspects 18 2.3.1. Introduction 18 2.3.2. Pharmacology 19 2.3.3. Pharmacokinetics 25 2.3.4. Toxicology 30 2.3.5. Ecotoxicity/environmental risk assessment 35 2.3.6. Discussion on non-clinical aspects 36 2.3.7. Conclusion on the non-clinical aspects 40 2.4. Clinical aspects 40 2.4.1. Introduction 40 2.4.2. Pharmacokinetics 41 2.4.3 (...) . Pharmacodynamics 52 2.4.4. Discussion on clinical pharmacology 52 2.4.5. Conclusions on clinical pharmacology 55 2.5. Clinical efficacy 56 2.5.1. Dose response study 56 2.5.2. Main studies 59 2.5.3. Discussion on clinical efficacy 87 2.5.4. Conclusions on the clinical efficacy 90 2.6. Clinical safety 91 2.6.1. Discussion on clinical safety 115 2.6.2. Conclusions on the clinical safety 120 2.7. Risk Management Plan 120 2.8. Pharmacovigilance 127 2.9. Product information 127 2.9.1. User consultation 127 2.9.2

2016 European Medicines Agency - EPARs

200. Briviact - brivaracetam

aspects 19 2.2.6. Recommendations for future quality development 19 2.3. Non-clinical aspects 19 2.3.1. Introduction 19 2.3.2. Pharmacology 20 2.3.3. Pharmacokinetics (PK) 23 2.3.4. Toxicology 24 2.3.5. Ecotoxicity/environmental risk assessment 32 2.3.6. Discussion on non-clinical aspects 33 2.3.7. Conclusion on the non-clinical aspects 37 2.4. Clinical aspects 38 2.4.1. Introduction 38 2.4.2. Pharmacokinetics 38 2.4.3. Pharmacodynamics 45 2.4.4. Discussion on clinical pharmacology 46 2.4.5 (...) . Conclusions on clinical pharmacology 47 2.5. Clinical efficacy 48 2.5.1. Dose response study(ies) 48 2.5.2. Main study(ies) 50 2.5.3. Discussion on clinical efficacy 86 2.5.4. Conclusions on the clinical efficacy 90 2.6. Clinical safety 90 2.6.1. Discussion on clinical safety 109 2.6.2. Conclusions on the clinical safety 112 2.7. Risk Management Plan 113 2.8. Pharmacovigilance 115 2.9. Product information 115 2.9.1. User consultation 115 2.9.2. Additional monitoring 115 Assessment report EMA/CHMP/822086

2016 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>